Idorsia Ltd (IDIA) - Total Assets
Based on the latest financial reports, Idorsia Ltd (IDIA) holds total assets worth CHF480.46 Million CHF (≈ $607.43 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Idorsia Ltd to assess how comfortably operating cash covers total debt obligations.
Idorsia Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Idorsia Ltd's total assets have evolved over time, based on quarterly financial data. See Idorsia Ltd (IDIA) shareholders funds for net asset value and shareholders' equity analysis.
Idorsia Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Idorsia Ltd's total assets of CHF480.46 Million consist of 48.0% current assets and 52.0% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 18.7% |
| Accounts Receivable | CHF51.92 Million | 11.1% |
| Inventory | CHF82.05 Million | 17.6% |
| Property, Plant & Equipment | CHF190.86 Million | 41.0% |
| Intangible Assets | CHF29.59 Million | 6.4% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Idorsia Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IDIA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Idorsia Ltd's current assets represent 48.0% of total assets in 2025, a decrease from 82.3% in 2016.
- Cash Position: Cash and equivalents constituted 18.7% of total assets in 2025, down from 79.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 41.0% of total assets.
Idorsia Ltd Competitors by Total Assets
Key competitors of Idorsia Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
Idorsia Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.60 | 0.57 | 8.12 |
| Quick Ratio | 1.08 | 0.38 | 8.12 |
| Cash Ratio | 0.00 | 0.00 | 0.55 |
| Working Capital | CHF89.86 Million | CHF-141.04 Million | CHF846.77 Million |
Idorsia Ltd - Advanced Valuation Insights
This section examines the relationship between Idorsia Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.65 |
| Latest Market Cap to Assets Ratio | 2.21 |
| Asset Growth Rate (YoY) | -7.9% |
| Total Assets | CHF465.88 Million |
| Market Capitalization | $1.03 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Idorsia Ltd's assets at a significant premium (2.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Idorsia Ltd's assets decreased by 7.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Idorsia Ltd (2016–2025)
The table below shows the annual total assets of Idorsia Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF465.88 Million ≈ $589.00 Million |
-7.91% |
| 2024-12-31 | CHF505.89 Million ≈ $639.59 Million |
+1.18% |
| 2023-12-31 | CHF500.00 Million ≈ $632.13 Million |
-44.70% |
| 2022-12-31 | CHF904.18 Million ≈ $1.14 Billion |
-39.03% |
| 2021-12-31 | CHF1.48 Billion ≈ $1.87 Billion |
+3.32% |
| 2020-12-31 | CHF1.44 Billion ≈ $1.81 Billion |
+42.94% |
| 2019-12-31 | CHF1.00 Billion ≈ $1.27 Billion |
-28.62% |
| 2018-12-31 | CHF1.41 Billion ≈ $1.78 Billion |
+8.89% |
| 2017-12-31 | CHF1.29 Billion ≈ $1.63 Billion |
+41.17% |
| 2016-12-31 | CHF915.12 Million ≈ $1.16 Billion |
-- |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more